TARO PHARM INDS
GenericsTARO PHARM INDS is a generic drug manufacturer focused on Neurology, Immunology, Cardiovascular.
TARO PHARM INDS's Key Drugs
TARO PHARM INDS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
TARO PHARM INDS's Recent FDA Approvals
New NDA/BLA approvals for TARO PHARM INDS over the last two years — novel drugs only, excluding generics and label supplements.
TARO PHARM INDS's Therapeutic Areas
TARO PHARM INDS's approved drugs and pipeline span 4 therapeutic areas, led by Neurology and Immunology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
TARO PHARM INDS's Top Competitors
TARO PHARM INDS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, PAI HOLDINGS PHARM, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
TARO PHARM INDS Pipeline Snapshot
Active clinical trials for TARO PHARM INDS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1998-03-11
- Latest
- 2026-04-01
- Applications
- 13